---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-043970"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:43:02.640556+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CareDx sells Lab Products to Eurobio for $170M; Q1 rev up 39% to $118M

## Summary
- Divests Lab Products (IVD kits) to Eurobio Scientific for $170M cash; expected close by end of Q3 2026.
- Preliminary Q1 2026 revenue ~$118M (+39% YoY); Testing Services revenue ~$91M (+48% YoY) on volume of ~54,900 (+17%).
- Patient & Digital Solutions revenue ~$16M (+33% YoY); Lab Products revenue ~$10M (-4% YoY).
- Cash, equivalents, and marketable securities ~$198M as of Mar 31, 2026.
- Retains exclusive North American distribution rights for certain Eurobio post-transplant monitoring IVD tests.

## SEC filing metadata
- accession: 0001104659-26-043970
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000110465926043970/0001104659-26-043970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000110465926043970/tm2611749d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-043970
- JSON: https://secwatch.observer/filing/0001104659-26-043970.json
- Plain text: https://secwatch.observer/filing/0001104659-26-043970.txt

## Source-grounded claims
- claim_id: 0bca605f383e41351644fce3c5b76513e86aa912
  claim: CareDx, Inc. reported first quarter of 2026 results: revenue approximately $118 million.
  evidence_excerpt: Revenue of approximately $118 million, growth of 39% year-over-year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000110465926043970/0001104659-26-043970-index.htm
- claim_id: 19bdd0b2d7ed2592179dfa48e9ec18aa4ad0b615
  claim: CareDx, Inc. entered into Purchase Agreement with Eurobio Scientific S.A. valued at $170 million in cash (effective 2026-04-15).
  evidence_excerpt: On April 15, 2026, CareDx, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software (the “Business”) for $170 million in cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000110465926043970/0001104659-26-043970-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.